[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

MCRT Webcast: Understanding Myeloma Stem Cell Transplantation- October 31, 2020

MCRT Webcast: Understanding Myeloma Stem Cell Transplantation- October 31, 2020 image

MCRT Webcast: Understanding Myeloma Stem Cell Transplantation- October 31, 2020

Roundtable
event Oct 31, 2020 / 09:00AM - 03:00PM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Autologous stem cell transplant (ASCT) is an essential part of many myeloma patients' treatment strategies.  Among the first questions physicians answer in the early stages of a myeloma diagnosis is whether patients are transplant eligible or ineligible.  Once considered controversial, ASCTs are now largely considered to be routine, safe, and essential to achieve deep remissions.  Second and tandem transplants are more prevalent.  Allogeneic transplants continue to be rare.  In the age of novel therapies, many patients speculate if ASCTs are even needed, some still fear them.  But the consensus of current practice still place transplant near the top of the list of effective treatments.

Drs. Natalie Callander, Mark Schroeder and Sergio Giralt address these and other issues concerning stem cell transplantation.  Dr. Zachary Crees leads a discussion about two case studies and all our engage in answering questions from viewers of the first session of the Myeloma Crowd Round Table.

Chimeric antigen receptor T (CAR T) cell therapies are a promising category of many immunotherapies currently being integrated into myeloma treatment.  CAR T cells identify targets on the surfaces of myeloma cells to deliver therapeutic agents to kill them.  Great progress has been made to manage this procedure.  In this Round Table session, four experts discuss the major issues in CAR T therapy.

Drs. Deepu Madduri, Nikhil Munshi and Ravi Vij provide a sweeping overview of the major issues in CAR T research and treatment.  Dr. Scott Goldsmith leads a discussion about two case studies of patients who have had CAR T cell treatment.  The full faculty concluded with questions from viewers in the second session of the Myeloma Crowd Round Table interactive webcast held on October 31, 2020.

 

 

Thanks to our Round Table sponsors

  

 

 

Virtual Round Table, October 31, 2020

Understanding Myeloma Stem Cell Transplantation

expand_more

The Promise of CAR T Cell Therapy

expand_more

Schedule & Agenda

Event panelist Dr. Natalie Callander, Dr. Mark Schroeder Dr. Sergio Giralt, Dr. Zachary Crees, Dr. Deepu Madduri, Dr. Nikhil Munshi, Dr. Ravi Vij
09:00 AM
Round Table
Dr. Natalie Callander, Dr. Mark Schroeder Dr. Sergio Giralt, Dr. Zachary Crees, Dr. Deepu Madduri, Dr. Nikhil Munshi, Dr. Ravi Vij

Speakers & Moderators

The panelist Natalie Callander, MD
Natalie Callander, MD

Natalie Callander, MD joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander graduated from Tufts University School of Medicine in Boston, MA, has completed residency at Bellevue Hospital in New York, as well as a Hematology/Oncology fellowship at the University of California-San Diego. Her board certifications include hematology, internal medicine, and medical oncology.

Read Bio
The panelist Mark Schroeder, MD
Mark Schroeder, MD

Mark Schroeder, MD, is Associate Professor of Medicine, Division of Oncology, Section of Blood and Marrow Transplantation at Washington University School of Medicine. Dr. Schroeder is a graduate of the University of Cincinnati College of Medicine and completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Washington University in St. Louis. He joined faculty at Washington University in 2009. He is a member of the Siteman Cancer Center and serves on the National Comprehensive Cancer Network Hematopoietic Cell Transplant Panel. Dr. Schroeder’s clinical research focuses on multiple myeloma, graft versus host disease, and stem cell transplant biology.

Read Bio
The panelist Ravi Vij, MD, MBA
Ravi Vij, MD, MBA

Ravi Vij, MD, MBA, is Professor of Medicine at the Washington University School of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia. Dr. Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He has research interests in multiple myeloma and AML/myelodysplastic syndromes. Dr. Vij serves on numerous committees including the International Myeloma Working Group (IWMG), the Core Transplant Myeloma and Leukemia Committees of the CALGB, the Steering Committee of the Multiple Myeloma Research Consortium, and the Myeloma Committee of the BMT Clinical Trials Network (CTN). His honors include the Multiple Myeloma Research Foundation Innovator Award (2013) and the Multiple Myeloma Research Consortium Center of Excellence Award (2011). He has authored more than 130 publications in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation. He has authored the book Contemporary Management of Multiple Myeloma and several chapters in books, including Multiple Myeloma and Plasma Cell Dyscrasias in the Washington Manual of Oncology. He has served as a review for journals including Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Experimental Hematology and Haematologica.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.